ChromaDex Corporation (NASDAQ:CDXC) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET

Company Participants

Tom Shumaker - Investor Relations

Robert Fried - Chief Executive Officer

Brianna Gerber - Interim Chief Financial Officer

Conference Call Participants

Jeff Cohen - Ladenburg Thalmann

Sean McGowan - ROTH Capital

Jeff Van Sinderen - B. Riley

Mitchell Pinheiro - Sturdivant & Company

Brian Nagel - Oppenheimer

Operator

Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's Third Quarter 2022 Conference Call. My name is Joelle, and I will be the conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded. This afternoon, ChromaDex issued a news release announcing the company's financial results for the third quarter of 2022. If you have not reviewed this information, both are available within the Investor Relations section of ChromaDex's website at www.chromadex.com.

I would now like to turn the conference call over to Tom Shumaker, LifeSci Advisors Agency, IR Counsel for ChromaDex. Please go ahead, Mr. Shumaker.

Tom Shumaker

Thank you. Good afternoon, and welcome to ChromaDex Corporation's third quarter 2022 results investor call. With us today are ChromaDex's Chief Executive Officer, Rob Fried; Interim Chief Financial Officer, Brianna Gerber; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao, who will join the call for Q&A.

Today's conference call may include forward-looking statements, including statements related to ChromaDex's research and development and clinical trial plans and the timing of results of such trials, the timing of future regulatory filings, the expansion of the sale of TRU NIAGEN in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interest and business prospects and opportunities as well as anticipated results of operations. Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties. Many factors could cause ChromaDex's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These risk factors include those contained in ChromaDex's quarterly report on Form 10-Q most recently filed with the SEC, including the effect of the COVID-19 pandemic as well as inflationary and adverse economic conditions on our business, results of operations, financial condition and cash flows. Please note that the company assumes no obligation to update any forward-looking statements after the date of this conference call to conform with the forward-looking statements' actual results or to changes in its expectations.